This Article Figures Only Full Text Full Text (PDF) View Current Clinical Collection-Atrial Fibrillation Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Burstein, B. Articles by Nattel, S. Search for Related Content PubMed Articles by Burstein, B. Articles by Nattel, S.

FOCUS ISSUE: ATRIAL FIBRILLATION: STATE-OF-THE-ART PAPER

Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation

Research Center and Department of Medicine, Montreal Heart Institute and Université de Montréal, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.

Manuscript received June 21, 2007; revised manuscript received August 16, 2007, accepted September 7, 2007.

^_* Reprint requests and correspondence: Dr. Stanley Nattel, 5000 Belanger Street East, Montreal H1T 1C8, Quebec, Canada. (Email: stanley.nattel{at}icm-mhi.org).

Atrial fibrillation (AF) is the most common arrhythmia in the clinical setting, and traditional pharmacological approaches have proved to have important weaknesses. Structural remodeling has been observed in both clinical and experimental AF paradigms, and is an important feature of the AF substrate, producing fibrosis that alters atrial tissue composition and function. The precise mechanisms underlying atrial fibrosis are not fully elucidated, but recent experimental studies and clinical investigations have provided valuable insights. A variety of signaling systems, particularly involving angiotensin II and related mediators, seem to be centrally involved in the promotion of fibrosis. This paper reviews the current understanding of how atrial fibrosis creates a substrate for AF, summarizes what is known about the mechanisms underlying fibrosis and its progression, and highlights emerging therapeutic approaches aimed at attenuating structural remodeling to prevent AF.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   AF = atrial fibrillation   AngII = angiotensin II   AT1 = angiotensin II type 1   CHF = congestive heart failure   ECM = extracellular matrix   PDGF = platelet-derived growth factor   TGF = transforming growth factor   VTP = ventricular tachypacing

This article has been cited by other articles:

				E. Anter and D. J. Callans Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort Circulation, October 6, 2009; 120(14): 1436 - 1443. [Full Text] [PDF]

				P. K. Mason and J. P. DiMarco New Pharmacological Agents for Arrhythmias Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 588 - 597. [Full Text] [PDF]

				M. M. Maleckar, J. L. Greenstein, W. R. Giles, and N. A. Trayanova K+ current changes account for the rate dependence of the action potential in the human atrial myocyte Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1398 - H1410. [Abstract] [Full Text] [PDF]

				D. J. Wilber Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late? J. Am. Coll. Cardiol., August 25, 2009; 54(9): 796 - 798. [Full Text] [PDF]

				P. Caso, R. Ancona, G. Di Salvo, S. Comenale Pinto, M. Macrino, V. Di Palma, A. D'Andrea, A.R. Martiniello, S. Severino, and R. Calabro Atrial reservoir function by strain rate imaging in asymptomatic mitral stenosis: prognostic value at 3 year follow-up Eur J Echocardiogr, August 1, 2009; 10(6): 753 - 759. [Abstract] [Full Text] [PDF]

				Y. Xie, A. Garfinkel, J. N. Weiss, and Z. Qu Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H775 - H784. [Abstract] [Full Text] [PDF]

				E. Anter, M. Jessup, and D. J. Callans Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic Circulation, May 12, 2009; 119(18): 2516 - 2525. [Full Text] [PDF]

				E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop Circulation, February 3, 2009; 119(4): 606 - 618. [Abstract] [Full Text] [PDF]

				B. Yang, Y. Lu, and Z. Wang Control of cardiac excitability by microRNAs Cardiovasc Res, September 1, 2008; 79(4): 571 - 580. [Abstract] [Full Text] [PDF]

				S. Nattel, B. Burstein, and D. Dobrev Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications Circ Arrhythm Electrophysiol, April 1, 2008; 1(1): 62 - 73. [Full Text] [PDF]